IBJNews

Group aims to cut costs of late-stage drugs

Back to TopCommentsE-mailPrintBookmark and Share

You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help.

But that’s exactly what happened last week when 10 major drug companies—including Indianapolis-based Eli Lilly and Co.—joined forces to cut costs out of clinical trials.

The 10 companies formed a not-for-profit organization called TransCelerate BioPharma Inc. Each company is contributing roughly a dozen employees to the project, as well as an undisclosed amount of money.

TransCelerate has a list of about 50 projects to work on to cut unnecessary costs from Phase 2 and Phase 3 clinical trials. Those two stages of human testing cost nearly $150 million per drug, according to studies by the Tufts Center for the Study of Drug Development.

“It’s significant,” said Jeff Kasher, vice president of Lilly’s Development Center of Excellence in Indianapolis, of the potential cost savings of the effort. He declined to quantify the expected savings, but he added, “I’m really, really confident that we’re going to deliver the goods from this group.”

TransCelerate has an initial three-year goal to show time and dollar savings in five areas. They include establishing a common supply model for comparison drugs—the existing medicines that experimental drugs are often tested against.

Also, TransCelerate plans to develop a common computer interface for physicians and their staffs conducting drug trials, which would recognize which companies and which drugs that particular medical center is doing work for and grant computer access to only those trials.

TransCelerate also intends to develop a new approach to monitoring the various sites that conduct clinical trials. Currently, some drug companies require extensive paper documentation of every aspect of a clinical trial while others do random sampling to generate statistics, which they use to monitor the clinical trial sites.

But TransCelterate will try to unite all 10 drug companies under a “risk-based monitoring approach” that documents aspects of drug trials that will be key in the regulatory review of the drug and pays less attention to less-critical areas.

“Everybody does it differently. Nobody really does it all that better than anybody else. But because we do it differently, we create confusion for a lot of the research sites,” Kasher said.

The 10 companies participating in TransCelerate are Lilly; Illinois-based Abbott Laboratories; United Kingdom-based AstraZeneca plc; Germany-based Boehringer Ingelheim GmbH; New York-based Bristol-Myers Squibb Co.; United Kingdom-based GlaxoSmithKline plc; New Jersey-based Johnson & Johnson; New York-based Pfizer Inc.; Genentech Inc.; which is a subsidiary of the Switzerland-based Roche Group; and France-based Sanofi-Aventis SA.

Many of them have struggled recently to launch enough new drugs to offset declining sales after their older blockbusters' patents expire. Lilly is in the midst of a four-year run in which it will see patents on five blockbusters expire, sapping as much as $10 billion in annual revenue.

Lilly has pushed more than 60 new drugs into experimental trials, but the cost of testing all of those in humans is pinching the company’s profits. A similar story is playing out at many of its competitors’.

“Even five years ago, this wouldn’t have happened,” Kasher said. “I’d say there’s frustration across the industry and pressure across the industry to accelerate the development of innovative medicines.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. In reality, Lilly is maintaining profit by cutting costs such as Indiana/US citizen IT workers by a significant amount with their Tata Indian consulting connection, increasing Indian H1B's at Lillys Indiana locations significantly and offshoring to India high paying Indiana jobs to cut costs and increase profit at the expense of U.S. workers.

  2. I think perhaps there is legal precedence here in that the laws were intended for family farms, not pig processing plants on a huge scale. There has to be a way to squash this judges judgment and overrule her dumb judgement. Perhaps she should be required to live in one of those neighbors houses for a month next to the farm to see how she likes it. She is there to protect the people, not the corporations.

  3. http://www.omafra.gov.on.ca/english/engineer/facts/03-111.htm Corporate farms are not farms, they are indeed factories on a huge scale. The amount of waste and unhealthy smells are environmentally unsafe. If they want to do this, they should be forced to buy a boundary around their farm at a premium price to the homeowners and landowners that have to eat, sleep, and live in a cesspool of pig smells. Imagine living in a house that smells like a restroom all the time. Does the state really believe they should take the side of these corporate farms and not protect Indiana citizens. Perhaps justifiable they should force all the management of the farms to live on the farm itself and not live probably far away from there. Would be interesting to investigate the housing locations of those working at and managing the corporate farms.

  4. downtown in the same area as O'malia's. 350 E New York. Not sure that another one could survive. I agree a Target is needed d'town. Downtown Philly even had a 3 story Kmart for its downtown residents.

  5. Indy-area residents... most of you have no idea how AMAZING Aurelio's is. South of Chicago was a cool pizza place... but it pales in comparison to the heavenly thin crust Aurelio's pizza. Their deep dish is pretty good too. My waistline is expanding just thinking about this!

ADVERTISEMENT